Investments, Funding & Disinvestment

The company plans to utilize two key facilities for this production: its Oxford, United Kingdom site and its Durham, North Carolina location.

The deal centers on one of SanegeneBio’s innovative RNAi programs and grants Genentech exclusive worldwide rights to develop and bring the treatment to market.

The new Irish facility aims to accelerate innovation and bring next-generation diagnostic capabilities to hospitals and laboratories worldwide.

The divestment positions Halo to focus on expanding into more complex drug-product manufacturing services while strengthening its presence in the sterile CDMO market.

Unlike traditional bypass surgery, which relies on a heart-lung machine, the off-pump approach allows surgeons to operate while the patient’s heart continues to beat naturally.

HC21 UK will showcase its capabilities at the ABHI UK Pavilion located in Hall 2, where members of its Irish management team will join forces to demonstrate the group’s comprehensive approach to market expansion.

CSPC is expected to receive an additional USD3.5 billion if the programs successfully meet development and regulatory milestones, in addition to royalties from any drugs approved under the partnership.

This new facility marks Lilly’s fourth major U.S. manufacturing project in recent years and adds to its broader domestic expansion strategy.

Both organizations plan to develop a long-term framework that facilitates knowledge exchange, clinical cooperation, and the joint development of physician training programs.

Kenmare Bio will obtain worldwide development and commercialization rights to an experimental oral small molecule known as FHND5032, with the exception of Greater China, where Chia Tai Feng Hai will retain control.